Glenview Trust’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $10.1M | Sell |
126,211
-5,219
| -4% | -$430K | 0.16% | 116 |
|
|
2025
Q4 | $11.2M | Sell |
131,430
-2,725
| -2% | -$224K | 0.17% | 110 |
|
|
2025
Q3 | $10.4M | Sell |
134,155
-16,401
| -11% | -$1.28M | 0.17% | 117 |
|
|
2025
Q2 | $11.8M | Sell |
150,556
-26,352
| -15% | -$1.97M | 0.2% | 101 |
|
|
2025
Q1 | $12.8M | Sell |
176,908
-180,654
| -51% | -$12.9M | 0.25% | 97 |
|
|
2024
Q4 | $26.5M | Sell |
357,562
-57,982
| -14% | -$4.06M | 0.5% | 47 |
|
|
2024
Q3 | $27.4M | Sell |
415,544
-11,215
| -3% | -$815K | 0.53% | 44 |
|
|
2024
Q2 | $39.4M | Buy |
426,759
+19,770
| +5% | +$1.75M | 0.79% | 30 |
|
|
2024
Q1 | $38.9M | Buy |
406,989
+20,266
| +5% | +$1.7M | 0.84% | 26 |
|
|
2023
Q4 | $29.5M | Sell |
386,723
-3,959
| -1% | -$275K | 0.72% | 38 |
|
|
2023
Q3 | $27.1M | Buy |
390,682
+29,436
| +8% | +$2.37M | 0.75% | 36 |
|
|
2023
Q2 | $34.1M | Buy |
361,246
+19,424
| +6% | +$1.69M | 0.93% | 28 |
|
|
2023
Q1 | $28.3M | Buy |
341,822
+22,017
| +7% | +$1.73M | 0.85% | 34 |
|
|
2022
Q4 | $23.9M | Buy |
319,805
+148,341
| +87% | +$11.4M | 0.79% | 37 |
|
|
2022
Q3 | $14.2M | Sell |
171,464
-5,900
| -3% | -$568K | 0.54% | 56 |
|
|
2022
Q2 | $16.9M | Sell |
177,364
-16,233
| -8% | -$1.68M | 0.62% | 48 |
|
|
2022
Q1 | $22.8M | Sell |
193,597
-33,156
| -15% | -$3.72M | 0.74% | 36 |
|
|
2021
Q4 | $29.4M | Sell |
226,753
-35,749
| -14% | -$4.17M | 0.97% | 25 |
|
|
2021
Q3 | $29.7M | Sell |
262,502
-13,430
| -5% | -$1.53M | 1.15% | 21 |
|
|
2021
Q2 | $28.6M | Buy |
275,932
+12,243
| +5% | +$1.15M | 1.1% | 24 |
|
|
2021
Q1 | $22.1M | Buy |
263,689
+2,635
| +1% | +$223K | 0.95% | 32 |
|
|
2020
Q4 | $23.8M | Buy |
261,054
+117
| +0% | +$9.71K | 1.11% | 23 |
|
|
2020
Q3 | $20.8M | Sell |
260,937
-967
| -0.4% | -$75.5K | 1.08% | 27 |
|
|
2020
Q2 | $18.1M | Buy |
261,904
+14,113
| +6% | +$1M | 1.03% | 29 |
|
|
2020
Q1 | $15.6M | Buy |
247,791
+8,709
| +4% | +$628K | 1.08% | 25 |
|
|
2019
Q4 | $18.6M | Sell |
239,082
-2,946
| -1% | -$230K | 1.04% | 28 |
|
|
2019
Q3 | $17.7M | Sell |
242,028
-5,649
| -2% | -$397K | 1.07% | 28 |
|
|
2019
Q2 | $15.3M | Buy |
247,677
+6,120
| +3% | +$370K | 0.95% | 30 |
|
|
2019
Q1 | $15.4M | Buy |
241,557
+4,089
| +2% | +$233K | 0.99% | 28 |
|
|
2018
Q4 | $12.1M | Buy |
237,468
+5,991
| +3% | +$303K | 0.9% | 32 |
|
|
2018
Q3 | $13.4M | Buy |
+231,477
| New | +$11.3M | 0.85% | 33 |
|
|
2018
Q2 | – | Sell |
-225,081
| Closed | -$10.5M | – | 322 |
|
|
2018
Q1 | $10.5M | Buy |
225,081
+15,219
| +7% | +$661K | 0.72% | 39 |
|
|
2017
Q4 | $7.88M | Buy |
209,862
+34,329
| +20% | +$1.26M | 0.54% | 62 |
|
|
2017
Q3 | $6.4M | Buy |
175,533
+153,306
| +690% | +$5.85M | 0.47% | 77 |
|
|
2017
Q2 | $876K | Hold |
22,227
| – | – | 0.07% | 174 |
|
|
2017
Q1 | $697K | Sell |
22,227
-840
| -4% | -$26.3K | 0.06% | 192 |
|
|
2016
Q4 | $720K | Buy |
+23,067
| New | +$747K | 0.06% | 184 |
|
|
2015
Q4 | $493K | Buy |
+18,732
| New | +$486K | 0.05% | 180 |
|
Other funds holding EW
VCM
VPM
Glenview Trust's EW Position: Q1 2026 in Review
Glenview Trust reduced its Edwards Lifesciences (EW) stake by 4% in Q1 2026, selling an estimated $430K and leaving 126,211 shares worth $10.1M. The position accounts for 0.16% of the portfolio, ranked #116.
Glenview Trust first reported a position in EW in Q4 2015 and has held it in 38 quarters since. The position peaked at $39.4M in Q2 2024. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Glenview Trust held 126,211 shares of Edwards Lifesciences worth $10.1M as of Q1 2026.
- Glenview Trust sold 5,219 Edwards Lifesciences shares in Q1 2026, an estimated $430K.
- Edwards Lifesciences made up 0.16% of Glenview Trust's portfolio in Q1 2026, its #116 holding.
- Glenview Trust first reported a position in Edwards Lifesciences in Q4 2015 and has held it in 38 quarters since.
- Glenview Trust's Edwards Lifesciences position peaked at $39.4M in Q2 2024.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Glenview Trust's 13F filing for Q1 2026, filed 8 May 2026.